PMC:7417114 / 57974-58439
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T283 | 424-439 | Body_part | denotes | glucuronic acid | http://purl.org/sig/ont/fma/fma82798 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T13272 | 289-296 | Chemical | denotes | N-oxide | http://purl.obolibrary.org/obo/CHEBI_35580 |
| T18122 | 291-296 | Chemical | denotes | oxide | http://purl.obolibrary.org/obo/CHEBI_25741|http://purl.obolibrary.org/obo/CHEBI_29356 |
| T40591 | 314-316 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
| T6497 | 359-368 | Chemical | denotes | masitinib | http://purl.obolibrary.org/obo/CHEBI_63450 |
| T63194 | 381-392 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
| T19833 | 407-418 | Chemical | denotes | metabolites | http://purl.obolibrary.org/obo/CHEBI_25212 |
| T42697 | 424-439 | Chemical | denotes | glucuronic acid | http://purl.obolibrary.org/obo/CHEBI_24298 |
| T32206 | 435-439 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1586 | 121-124 | Species | denotes | dog | Tax:9615 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T169 | 222-235 | http://purl.obolibrary.org/obo/GO_0070988 | denotes | demethylation |
| T170 | 297-306 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | formation |
| T171 | 308-326 | http://purl.obolibrary.org/obo/GO_0052697 | denotes | phase II metabolic |
| T172 | 308-326 | http://purl.obolibrary.org/obo/GO_0051923 | denotes | phase II metabolic |
| T173 | 344-355 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugation |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T482 | 0-19 | Sentence | denotes | Masitinib (Masivet) |
| T483 | 20-465 | Sentence | denotes | (AB Science) Absorption: mean Tmax between 1.7 and 4.7 h; following oral administration of 8.4mg/kg (dog); good absorption/exposure with AUC (0-24 h)=4045 ng*h/mL Phase I metabolic pathways: reduction, demethylation, hydroxylation, oxidative deamination, oxidation and N-oxide formation; phase II metabolic pathways: direct conjugation of masitinib, N-demethyl metabolites and oxidative metabolites with glucuronic acid Information not available |